What Is Myo & D-Chiro Inositol and How Do They Work?

Myo-inositol and D-chiro-inositol are two closely related molecules that belong to the inositol family, a group of naturally occurring compounds with structures resembling simple sugars. Both act as second messengers in insulin signaling, meaning they relay insulin’s instructions once it docks onto a cell. They have overlapping but distinct jobs: myo-inositol is the more abundant form, involved in everything from glucose uptake to egg maturation in the ovaries, while D-chiro-inositol focuses more narrowly on how the body stores and processes glucose. Their interplay, and the specific ratio in which the body produces them, turns out to matter a great deal for conditions ranging from polycystic ovary syndrome to gestational diabetes.

Two Versions of the Same Backbone

Inositols are a family of compounds that share a six-carbon ring. Myo-inositol is the most common member, found widely in both plants and animals, and it derives directly from glucose through a normal metabolic pathway.¹ D-chiro-inositol is its less abundant sibling. Structurally, the two molecules are nearly identical, differing only in the orientation of a single hydroxyl group on their ring. That slight twist changes how each molecule fits into enzyme active sites and receptor pathways, giving them different biological roles despite coming from the same parent compound.

Your body makes most of the myo-inositol it needs internally, though you also get it from food. Grains, beans, citrus fruits, and nuts are all reasonable dietary sources. D-chiro-inositol is not independently synthesized. Instead, your tissues produce it by converting myo-inositol through an enzyme called an epimerase, and that conversion is driven by insulin itself.

How They Act as Insulin’s Messengers

When insulin binds to a cell, it triggers a cascade of internal signals. Myo-inositol and D-chiro-inositol sit at key junctures of that cascade. D-chiro-inositol, discovered as a component of a putative mediator of insulin action, accelerates the activation of enzymes involved in glucose disposal, including glycogen synthase and pyruvate dehydrogenase.² In plain terms, D-chiro-inositol helps cells follow through on insulin’s instruction to either store glucose as glycogen or burn it for energy. Myo-inositol, meanwhile, participates in a broader set of signaling pathways. It is a precursor for phosphoinositides, a class of signaling molecules that relay messages from hormones like insulin, follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). This is why myo-inositol shows up in research on ovarian function, thyroid health, and brain chemistry, not just blood sugar.

The Epimerization Bottleneck

Since D-chiro-inositol comes from myo-inositol, the conversion between them is a critical step. In healthy tissue, insulin stimulates an epimerase enzyme that flips myo-inositol into D-chiro-inositol at a rate appropriate to the tissue’s needs. But research in animal models of type 2 diabetes tells a different story. In diabetic rats, the conversion of myo-inositol to D-chiro-inositol was dramatically reduced across liver, muscle, and fat tissue, dropping from baseline rates of around 20–25% conversion down to under 5%.³ The epimerase enzyme itself showed significantly reduced activity in those insulin-sensitive tissues.

This creates a bottleneck. When insulin resistance sets in, the very enzyme that should be producing D-chiro-inositol slows down. The result is a tissue-level deficit of D-chiro-inositol, which further impairs the cell’s ability to carry out insulin’s glucose-disposal instructions. Researchers believe this deficit may partly explain why insulin resistance is self-reinforcing: the worse it gets, the less D-chiro-inositol gets made, and the less effective insulin signaling becomes.

Why the Kidneys Make Things Worse in Diabetes

On top of impaired production, people with diabetes lose more inositol through their urine. In animal models, D-chiro-inositol excretion was hit far harder than myo-inositol. Diabetic rat kidneys excreted D-chiro-inositol at roughly 4 times the rate of non-diabetic kidneys, compared to only 1.7 times for myo-inositol.⁴ High blood sugar made D-chiro-inositol losses even worse, while myo-inositol excretion remained relatively stable. In more severe diabetes models, the numbers were staggering: urinary D-chiro-inositol excretion increased by hundreds of fold compared to non-diabetic controls.⁵ So diabetes attacks inositol balance from two directions: less gets made in the tissues and more gets flushed out by the kidneys.

The 40:1 Ratio and PCOS

Polycystic ovary syndrome is probably the most well-known context for inositol supplementation, and it is where the ratio question becomes clinically important. In a healthy body, the circulating ratio of myo-inositol to D-chiro-inositol sits at roughly 40 to 1. Clinical evidence has shown that supplementing these two forms in that same 40:1 ratio is the most effective combination for restoring ovulation in women with PCOS.⁶ Trials have found this combination effective at restoring both ovarian function and metabolic balance.⁷

The reason this ratio matters so much has to do with a paradox in how the ovaries handle these molecules.

The Ovarian Paradox

In most insulin-resistant tissues, the problem is too little D-chiro-inositol. But the ovaries appear to have the opposite problem. Researchers have hypothesized that in women with PCOS, the epimerase enzyme in ovarian tissue is actually overactive, converting too much myo-inositol into D-chiro-inositol.⁸ This creates a local myo-inositol deficiency in the ovaries, which is a problem because the ovaries specifically need myo-inositol to respond to FSH, the hormone that drives egg maturation.⁹ In the ovary, myo-inositol mediates the granulosa cell response to FSH, playing a central role in oocyte maturation.¹⁰

This is why supplementing D-chiro-inositol alone, especially at high doses, can backfire. Research has shown that increasing D-chiro-inositol dosage progressively worsens oocyte quality and ovarian response in non-obese, non-insulin-resistant PCOS women undergoing IVF.¹¹ The combined 40:1 approach avoids this trap. It gives the body enough D-chiro-inositol to support insulin signaling in muscle, liver, and fat, while preserving the myo-inositol supply that the ovaries need.¹²

Gestational Diabetes Prevention

The insulin-sensitizing effects of inositol have attracted interest for preventing gestational diabetes, particularly in women with known risk factors like obesity. A meta-analysis pooling data from randomized controlled trials found that inositol supplementation beginning around the 12th–13th week of pregnancy significantly reduced the risk of gestational diabetes. Myo-inositol supplementation, specifically, cut the risk by roughly 70%.¹³ One individual trial of obese pregnant women found that the gestational diabetes rate was 14% in the myo-inositol group compared to about 34% in the control group, alongside a meaningful improvement in insulin resistance.¹⁴

The evidence for D-chiro-inositol in pregnancy is thinner — only one trial in the meta-analysis examined it, also finding a beneficial effect, but a single study is not strong ground for firm recommendations. Most of the pregnancy research centers on myo-inositol.

Effects on Blood Lipids and Blood Pressure

Insulin resistance does not just affect blood sugar. It drives up triglycerides, raises LDL cholesterol, and pushes blood pressure higher. Inositol supplementation appears to help on several of these fronts. A systematic review of randomized controlled trials in patients with metabolic conditions found significant reductions in triglycerides, total cholesterol, and LDL cholesterol, though HDL cholesterol was not affected.¹⁵

A more recent and larger meta-analysis confirmed reductions in triglycerides (by about 30 mg/dL on average) and total cholesterol (about 18 mg/dL), with modest improvements in LDL and HDL as well. That analysis also found that inositol lowered systolic blood pressure by about 5 mmHg and diastolic blood pressure by about 6 mmHg, though the certainty of evidence for the blood pressure findings was lower.¹⁶ These are not dramatic single-intervention numbers, but they are in the range that adds up when combined with other lifestyle or pharmacological measures.

Male Fertility

Most inositol research focuses on women, but myo-inositol also plays a role in sperm function. Myo-inositol is present at high concentrations in seminal fluid, and it participates in sperm cell signaling and motility. A randomized clinical trial in men with low sperm count and poor motility found that myo-inositol treatment significantly improved sperm motility and doubled the pregnancy rate in couples undergoing intrauterine insemination: 18% in the treatment group versus 9% in the control group.¹⁷ A broader review of the literature reported improvements in sperm motility in both fresh and frozen-thawed semen samples, along with better sperm performance in both natural and assisted conception settings.¹⁸

Research in this area is still smaller in volume than the PCOS literature, but the direction of findings is consistent enough that myo-inositol has started appearing in some male fertility supplement formulations.

Thyroid Health and Autoimmunity

Myo-inositol’s role as a precursor to signaling molecules extends to the thyroid gland. TSH, the hormone that tells the thyroid to produce thyroid hormones, relies on the same phosphoinositide signaling pathway that myo-inositol feeds into. Myo-inositol is also involved in producing hydrogen peroxide within thyroid cells, a step required for thyroid hormone synthesis. A depletion of myo-inositol or impaired inositol-dependent TSH signaling may therefore contribute to hypothyroidism.¹⁹

Clinical studies have tested myo-inositol combined with selenium in patients with subclinical hypothyroidism, many of whom also had autoimmune thyroiditis (Hashimoto’s). The combination led to significant reductions in TSH levels and a decline in antithyroid antibodies, suggesting both a direct hormonal effect and an immune-modulating one.²⁰ This is a relatively newer area of research compared to the PCOS and metabolic work, but it has generated real clinical interest, especially because subclinical hypothyroidism is common in women of reproductive age and often overlaps with PCOS itself.

Absorption, Transporters, and “Inositol Resistance”

To work, inositol has to get from your gut into your bloodstream. In the small intestine, myo-inositol is absorbed through a specific sodium-coupled transporter called SMIT2, which is exclusively responsible for apical myo-inositol transport in rat intestine.²¹ D-chiro-inositol also uses SMIT2 for absorption. Other sugar transporters in the gut lining, like those that handle glucose and fructose, did not contribute meaningfully to inositol uptake.

The practical upshot is that absorption can become a bottleneck for some people. A subset of PCOS patients do not respond to standard myo-inositol supplementation — their blood levels simply do not rise as expected. Researchers have termed this “inositol resistance.” One approach that has shown promise is pairing myo-inositol with alpha-lactalbumin, a whey protein that appears to improve the passage of molecules across biological barriers, including the intestinal lining. In one study, 86% of myo-inositol-resistant PCOS patients ovulated after switching to the myo-inositol plus alpha-lactalbumin combination, and their plasma myo-inositol levels rose significantly from baseline.²² This combination has been validated in multicenter work across different populations.²³

If you have been taking myo-inositol for several months without improvement, inositol resistance and the alpha-lactalbumin workaround are worth discussing with your provider.

Mental Health Connections

Myo-inositol has a long, if somewhat uneven, history in psychiatric research. It is present in high concentrations in the brain, where it participates in the same phosphoinositide second-messenger systems used by serotonin and other neurotransmitters. Imaging and biomolecular studies have pointed to a role for altered inositol levels in mood disorders.²⁴ High-dose myo-inositol (often in the range of 12–18 grams per day) was tested in clinical trials for depression, panic disorder, and obsessive-compulsive disorder in the 1990s and 2000s, with some positive results in earlier small trials. However, the evidence has remained inconsistent, and myo-inositol has not become a standard psychiatric treatment. The interest here is more about understanding the biology of mood disorders than about inositol as a standalone therapy.

Safety and Typical Doses

Myo-inositol is generally well tolerated. The doses used in most PCOS and metabolic trials range from 2 to 4 grams of myo-inositol per day, often combined with 50 to 100 milligrams of D-chiro-inositol to achieve the 40:1 ratio. At these levels, side effects are uncommon. Higher doses, particularly above 12 grams per day (the kind used in psychiatric research), are more likely to cause mild gastrointestinal effects like nausea, gas, or loose stools. Because both forms are naturally present in the body and in food, toxicity concerns are minimal at standard supplementation levels.

For pregnant women, the evidence on myo-inositol’s safety profile is reassuring across the trials conducted to date, though anyone considering supplementation during pregnancy should involve their healthcare provider. D-chiro-inositol in pregnancy has not been studied nearly as extensively, and given the ovarian paradox findings, it is worth being cautious with high standalone doses of D-chiro-inositol in reproductive contexts.

Neonatal Research and Early-Life Uses

Inositol is not only relevant for adults. Premature infants have lower inositol levels than full-term babies, and early research explored whether supplementation could reduce complications like retinopathy of prematurity and respiratory distress syndrome. One of the landmark studies, published in the early 1990s, found that inositol-supplemented premature infants had less retinopathy, and none developed the most severe form, compared to 9% in the placebo group.²⁵

However, larger and more recent trials have not replicated those early dramatic results. A Cochrane systematic review concluded that, based on all randomized controlled trials to date, inositol supplementation does not produce important reductions in the rates of infant death, severe retinopathy, brain hemorrhage, chronic lung disease, or sepsis in preterm infants.²⁶ The pharmacokinetics of myo-inositol in extremely preterm infants have been studied to pave the way for further efficacy trials.²⁷ The neonatal story is a good reminder that promising early results in small trials do not always survive larger, more rigorous testing, and the field is still looking for the right dose, timing, and patient population.